This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Christmas has always been more than presents under a tree. It is the flight home after a year apart, the dinner table with an extra leaf pulled out, the gifts that delight grandchildren, the church service on Christmas Eve, and the quiet satisfaction of being able to give generously without wondering how the credit card bill will look in January. As those traditions have become more expensive, many families have found themselves scaling back, not because they value Christmas less, but because it costs more to celebrate it the way they remember.
The average winter holiday budget is not the same as the full cost of Christmas. NRF’s 2025 survey put planned spending on gifts, food, decorations, and other seasonal items at about $890 per person. Once travel, hosting, charitable giving, and family traditions are included, however, a travel-heavy family Christmas can easily approach $5,000. It is a recurring expense many households never calculate because it arrives in dozens of small purchases spread over several weeks. And, for families who don’t plan for it financially, Christmas can become something they’re still paying for well into the next year.
So how much capital would be needed to help pay for Christmas each year without routinely drawing down principal? Use $5,000 a year as the target. The math gets interesting fast.
The Sleep-At-Night Tier: 3% To 4% Yield At a 3.5% yield, $5,000 a year requires roughly $143,000 in capital. At 4%, the number drops to $125,000. This is the dividend growth tier: broad equity income funds, blue-chip aristocrats, and quality consumer staples.
Coca-Cola (NYSE: KO) raised its quarterly payout to $0.53 in 2026, marking its 64th consecutive annual dividend increase. PepsiCo (NASDAQ: PEP) announced its 54th consecutive annual increase, lifting the dividend to $1.48 per quarter. At recent yields of roughly 2.6% for Coca-Cola and about 4.1% for PepsiCo, a $125,000 position split evenly between the two would produce about $4,200 a year before taxes, not $5,000.
The Middle Path: 5% To 7% Yield Step the yield to 6% and the capital required falls to roughly $83,000. This is the territory of net lease REITs, regulated utilities, and preferred shares.
Realty Income (NYSE: O) calls itself the Monthly Dividend Company for a reason: it has declared more than 670 consecutive monthly dividends, with a recent payment of $0.271 per share and a yield around 5.2%. Regulated utilities like Southern Company (NYSE: SO) and Duke Energy (NYSE: DUK) pay quarterly distributions backed by rate-regulated cash flows. Southern raised its annualized dividend to $3.04 in 2026, while Duke’s quarterly dividend is $1.065.
The High-Yield Lane: 8% To 12% At a 10% yield, $5,000 a year takes only $50,000. The catch is that the principal often does not grow, and sometimes shrinks. Main Street Capital (NYSE: MAIN) paid regular monthly dividends of $0.26 per share in the second quarter of 2026, then raised the regular monthly dividend to $0.265 for the third quarter, with $0.30 supplemental dividends declared for March and June. Mortgage REITs and leveraged covered-call funds can stretch yields higher, but distributions can be cut and net asset value can grind lower over time.
Don’t Miss These Quiet Advantages A 10% yield with no growth pays $5,000 every December for a decade if the payout holds. A 3% yield that starts at $5,000 and grows 8% a year would pay about $10,000 by year 10 and about $21,600 by year 20. The high-yield portfolio still pays $5,000 if the distribution never changes; the dividend-growth portfolio becomes a much larger income source if the growth rate persists.
The other quiet advantage is psychological. Monthly payers like Realty Income and Main Street Capital deposit a check 12 times a year, which can help match a sinking-fund approach to holiday spending. The 10-year Treasury recently yielded about 4.4%, but a Treasury coupon does not rise after purchase. Some equity dividends can rise over time, but only when the business and board support the increase.
Turn Christmas Into a Planned Income Need Price your actual Christmas. Pull last year’s November and December credit card statements and add gifts, travel, hosting costs, decorations, charitable giving, and the extra grocery runs that never make it into the “gift” budget. The real number is often higher than the number families carry in their heads. Compare a 3% grower against a 10% payer over a real holding period. Total return matters more than the headline yield, and the compounding chart often favors the lower starting yield when dividend growth and principal appreciation persist.
Layer the payment schedule. Pair a monthly payer with quarterly dividend growers so cash arrives throughout the year instead of in one lump. That can make the portfolio easier to use as a Christmas sinking fund without forcing December sales. A Holiday Fund That Can Grow With the Tradition The best Christmas portfolio is not the one with the flashiest yield. It is the one that turns a recurring family expense into a planned income need, then matches that need with the right mix of yield, growth, diversification, and tax awareness. A generous holiday does not have to be funded by December panic. It can be built all year, one dividend at a time.
Contact [email protected] for any questions or corrections.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hub Group To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Hub Group between April 28, 2023 and May 11, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 11, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG) and reminds investors of the August 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Hub Group’s financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements caused by the premature and incorrect recognition of certain transactions concerning, among other things, Hub Group’s operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth; and (2) Hub Group’s financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements caused by the understatement of purchased transportation costs and accounts payable concerning, among other things, Hub Group’s operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth.
On February 5, 2026, Hub Group announced that the Company's financial statements for the first three quarters of 2025 should not be relied upon and would be restated due to "an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025." The Company revealed that its reports for those quarters "were in each case materially misstated due to the aforementioned error and should no longer be relied upon" and that "the Company [wa]s also continuing to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting and appropriate remediation steps." The Company also estimated that "[t]he total amount of the reduction to accounts payable and purchased transportation costs related to this issue that was recorded during these periods is $77 million."
This news caused the price of Hub Group stock to decline roughly 18%, from $51.33 per share at close on February 5, 2026, to $41.96 per share at close on February 6, 2026.
On May 12, 2026, Hub Group announced that it had "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported," causing its 2023 and 2024 annual reports filed with the SEC to be "materially misstated," such that they "should no longer be relied upon." The Company did not quantify the expected misstatement, although it "expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023."
This news caused the price of Hub Group stock to decline a further 13%, from $41.86 per share at close on May 11, 2026, to $36.62 per share at close on May 12, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Hub Group’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Hub Group class action, go to www.faruqilaw.com/HUBG or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Hub Group Securities Class Action Lawsuit:
What is the Hub Group securities fraud lawsuit about?
The lawsuit alleges Hub Group made misleading statements about revenue recognition, transportation costs, accounts payable, internal controls, and financial reporting, causing multiple financial statements to contain material accounting misstatements.
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Hub Group (NASDAQ: HUBG) securities between April 28, 2023 and May 11, 2026 may be eligible to participate if they suffered losses related to the alleged misconduct.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the proposed class and helps oversee the litigation. Eligible investors must file a motion with the court by August 28, 2026. Investors can share in any recovery without serving as lead plaintiff.
What should investors do if they purchased Hub Group stock during the Class Period?
Investors should review their trading records, preserve relevant documents, and evaluate their legal rights. Those who suffered losses may wish to consult counsel regarding participation in the lawsuit or seeking lead plaintiff status before the deadline.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for clients. The firm can evaluate your potential claims and explain your legal options at no upfront cost.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Insulet To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Insulet between February 21, 2025 and May 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 11, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) and reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."
On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."
On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Insulet’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Insulet class action, go to www.faruqilaw.com/PODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Insulet Securities Class Action Lawsuit:
What is the Insulet securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased Insulet securities during the Class Period. The lawsuit alleges that Insulet's manufacturing controls and procedures were defective, and that this deficiency allegedly created a foreseeable, heightened risk that one or more Insulet products would be found to violate applicable safety regulations or pose a risk of injury to patients. The complaint further alleges that, as a result, Insulet's public statements during the Class Period were materially false and misleading. The alleged truth began to emerge through two separate voluntary Medical Device Corrections disclosed by Insulet in March and May 2026, each involving manufacturing issues with specific lots of Omnipod® products, which were followed by significant declines in Insulet's stock price.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities on the NASDAQ exchange between February 21, 2025 and May 26, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased during the Class Period may be entitled to share in any recovery that may be obtained. Investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Additional eligibility considerations may apply, and investors are advised to consult with counsel to evaluate their specific circumstances.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative party who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy, selection of counsel, and settlement negotiations. Under the Private Securities Litigation Reform Act, any member of the proposed class may move the court for appointment as lead plaintiff, and the court will generally appoint the movant with the largest financial interest in the relief sought who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff in this action is August 31, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class or share in any recovery that may result from the litigation.
What should investors do if they purchased Insulet stock during the Class Period?
Investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 are encouraged to review their brokerage and trading records to confirm whether their purchases fall within the Class Period. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications related to their Insulet holdings. Given that the lead plaintiff motion deadline is August 31, 2026, investors who wish to be considered for appointment as lead plaintiff should act promptly to avoid missing that deadline. Investors interested in learning more about the lawsuit or their potential legal rights and options may contact Faruqi & Faruqi, LLP to discuss their circumstances prior to the deadline, though retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Insulet securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5
The artificial intelligence narrative is fracturing right before our eyes. Over the last two years, the market has focused obsessively on centralized hyperscale training. That phase required sprawling data centers digesting trillions of parameters.
Enterprise IT departments are now discovering the hidden costs of that centralized model. Prohibitive data egress fees, latency bottlenecks, and strict data governance mandates are driving a wave of cloud repatriation. Corporate leaders want to bring their AI models in-house. They are seeking sovereign AI.
Get Super Micro Computer alerts:
Sovereign Territory: Bringing Proprietary Data Back HomeSuper Micro Computer Today
SMCI
Super Micro Computer
$28.31 +0.07 (+0.25%)
As of 07/10/2026 04:00 PM Eastern
52-Week Range$19.48▼
$62.36P/E Ratio14.98
Price Target$38.57
Super Micro Computer NASDAQ: SMCI is pivoting to capture this enterprise migration. The company is deploying turnkey hardware that transforms the hardware builder into a high-margin ecosystem provider.
Sovereign AI requires proprietary enterprise data to remain within tightly controlled environments rather than being processed by external cloud hyperscalers.
When a corporation trains or fine-tunes a localized model on its own private data, sending that data back and forth to a centralized public cloud incurs a significant financial burden. Cloud providers charge data egress fees every time information leaves their servers. Over time, for persistent inferencing workloads, these fees can cannibalize the return on investment.
We are watching a structural shift in the physical economy. Major consumer and industrial brands are moving away from the cloud toward localized infrastructure. As recently exemplified by Starbucks NASDAQ: SBUX, retail operators are realizing that running localized algorithms for inventory management or customer behavior modeling is more cost-effective when executed on-premise or at the network edge.
This transition creates a severe technical challenge. Historically, localized deployment required specialized on-site IT engineering teams to manage storage arrays and compute clusters. Retail stores and factory floors simply lack the physical space or engineering talent to maintain traditional server racks.
To make the shift to sovereign AI, businesses need infrastructure that acts like an appliance. They need to plug it in, turn it on, and let it run autonomously.
The Kubernetes Cure: Healing the Localized Storage HeadacheThis acceleration toward localized AI frames Super Micro Computer's recent product launch. SMCI unveiled a turnkey Kubernetes Edge AI appliance in direct collaboration with Red Hat OpenShift and Portworx. This is not another bare-metal server box, but rather a fully validated, self-healing infrastructure solution.
By utilizing Kubernetes, enterprises ensure their containerized models remain cloud-agnostic. This capability allows businesses to migrate computing power to localized clusters without fracturing their core application architecture.
SMCI is bridging the gap for companies looking to exit the cloud by offering an off-ramp that works right out of the box. Portworx provides a software-defined, aggregated local storage layer that operates autonomously. If a network outage hits a retail location, the local data platform heals itself and keeps the inferencing workloads running without requiring a frantic call to a remote IT team. The integration of Red Hat OpenShift provides the enterprise-grade management layer.
From a fundamental perspective, this appliance alters SMCI's value proposition. Commodity server hardware is inherently vulnerable to pricing wars and severe margin compression. By bundling bare-metal hardware with premium enterprise software, SMCI captures integration value that previously leaked to third-party system integrators. SMCI can defend and expand its gross margins, charging a premium for the convenience and reliability of a fully integrated edge ecosystem.
Valuation Disconnect: Buying the Artificial Intelligence DipDespite this formidable product pipeline, the market has heavily discounted SMCI. Shares have contracted by 30% over the last 30 days, pushing the trailing price-to-earnings (P/E) ratio down to just 15. Bearish sentiment has aggressively accelerated, with short interest swelling to roughly 19% of the public float. A low days-to-cover ratio of 1.2 to 1.9 indicates high liquidity, largely a residual benefit of the 10-for-1 stock split executed in October 2024.
This elevated short positioning relies heavily on the narrative that Super Micro Computer is burning through cash to secure components. The primary target of market skepticism is the $7 billion equity and equity-linked financing initiative announced in early June 2026. Critics view this capital raise as a sign of financial strain. However, a pragmatic look at the balance sheet reveals a different story.
The capital is structured to finance component procurement for an estimated $39 billion AI server order backlog. Financing a $39 billion backlog is not a sign of weakness, but instead a signal of SMCI's moat.
Competitors cannot easily replicate the capital intensity required to fulfill enterprise demand at this scale. While short sellers are betting that SMCI will struggle with margin compression and share dilution, institutional entities are accumulating shares.
The deployment of high-margin edge appliances offers the specific catalyst needed to drive upward earnings revisions. If the edge pivot succeeds in expanding net margins beyond the current 3.70%, that heavy bearish positioning could easily unravel in a short squeeze scenario.
The Forward Edge: Claiming the Throne in Localized ComputeThe underlying demand for the hardware layer of the computing supercycle remains fully intact, but the market is heavily segmented. We can see a distinct divergence in valuation multiples when comparing Super Micro Computer to legacy competitors.
Dell Technologies Today
DELL
Dell Technologies
$435.14 -15.08 (-3.35%)
As of 07/10/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$110.22▼
$469.47Dividend Yield0.58%
P/E Ratio34.56
Price Target$492.76
Dell Technologies NYSE: DELL is currently the primary competitor in the hardware server market, with shares up roughly 20% over the trailing 30 days. Dell Technologies recently raised its full-year revenue guidance on the back of $16.13 billion in optimized server revenue. The market applies a significant premium to Dell Technologies, trading at a forward P/E near 25x while yielding a recently increased dividend. Similarly, Hewlett Packard Enterprise NYSE: HPE has rebounded nicely, supported by growth in its networking segment.
SMCI is currently trading at a steep discount to these peers, presenting an intriguing dynamic. SMCI is battling formidable competition and absorbing the broader market premium, yet its engineering velocity and modular architecture provide a distinct fundamental edge.
Coupling rapid hardware deployment with validated, plug-and-play Kubernetes environments establishes a highly compelling offering for organizations executing cloud repatriation strategies. Investors might consider adding SMCI to their watchlists as the enterprise migration toward sovereign AI continues to unfold, and closely monitor the upcoming August earnings report to see whether these new high-margin edge appliances begin lifting overall profitability.
Should You Invest $1,000 in Super Micro Computer Right Now?Before you consider Super Micro Computer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Super Micro Computer wasn't on the list.
While Super Micro Computer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Peabody Energy To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Peabody Energy between October 14, 2024 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 11, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Peabody Energy Corporation (“Peabody Energy” or the “Company”) (NASDAQ: BTU) and reminds investors of the August 24, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Peabody Energy's Centurion mine and the multitude of issues causing delays to the ramp-up and the return to full longwall production dates. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Peabody Energy's securities at artificially inflated prices.
On March 30, 2026, Peabody Energy issued a press release lowering guidance pertaining to Centurion mine's expected first quarter 2026 output, announcing that sales volume from the Centurion mine was expected to deliver approximately 250,000 tons in the first quarter due to "greater-than-anticipated mine commissioning challenges" (compared to previous estimates of around 700,000 tons). On this news, Peabody Energy's stock price fell $3.82, or approximately 9.7%, to close at $35.68 per share on March 30, 2026.
On May 5, 2026, Peabody Energy issued a press release disclosing the Company's failure to ramp-up Centurion by the long-awaited March 2026 deadline and cutting guidance related to full year met segment volumes to reflect the increased cost and substantial volume decrease, reducing the full year sales outlook for Centurion to 2.5 million tons compared to the original expectation of 3.5 million tons. On this news, Peabody Energy's stock price fell $1.52, or 5.7%, to close at $25.00 per share on May 5, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Peabody Energy’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Peabody Energy class action, go to www.faruqilaw.com/BTU or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Peabody Energy Securities Class Action Lawsuit:
What is the Peabody Energy securities fraud lawsuit about?
The lawsuit alleges that Peabody Energy Corporation (NASDAQ: BTU) and certain of its officers and directors made materially false and misleading statements and/or concealed material adverse facts concerning the true condition of the Company's Centurion mine, including the nature and severity of issues allegedly causing delays to its ramp-up and return to full longwall production. The complaint alleges that, throughout the Class Period, defendants provided investors with overwhelmingly positive statements about the Centurion mine while purportedly withholding information about the multitude of operational challenges affecting it. These allegedly false and misleading statements are said to have caused investors to purchase Peabody Energy securities at artificially inflated prices. The inflation in the stock price allegedly began to correct when Peabody Energy disclosed, on March 30, 2026, that first quarter 2026 output from the Centurion mine was expected to reach only approximately 250,000 tons — well below prior estimates of approximately 700,000 tons — due to "greater-than-anticipated mine commissioning challenges," and further when the Company disclosed on May 5, 2026 that it had failed to ramp up the mine by its March 2026 deadline and cut its full-year sales outlook for Centurion from 3.5 million tons to 2.5 million tons.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Peabody Energy Corporation (NASDAQ: BTU) securities on the NASDAQ between October 14, 2024 and May 4, 2026, inclusive, may be eligible to participate in this lawsuit as members of the proposed class. Eligibility to participate is not limited to investors who seek appointment as lead plaintiff; any qualifying class member may share in any recovery that may ultimately be obtained. Investors who purchased Peabody Energy securities during the Class Period and suffered losses are encouraged to review their transaction records to determine whether they fall within the defined class. Participation in a class action does not require that an investor take any individual legal action or incur separate legal fees to potentially benefit from any recovery achieved on behalf of the class.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy and the selection of lead counsel. Any class member who purchased Peabody Energy securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, and courts typically appoint the movant with the largest financial interest in the outcome of the litigation who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff is August 24, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class and share in any recovery that may result from the litigation — class members who do not serve as lead plaintiff retain the ability to benefit from any settlement or judgment.
What should investors do if they purchased Peabody Energy stock during the Class Period?
Investors who purchased Peabody Energy Corporation (NASDAQ: BTU) securities between October 14, 2024 and May 4, 2026, inclusive, are encouraged to promptly review their brokerage records and account statements to confirm the dates and prices at which they acquired and, if applicable, sold their shares. Investors should take steps to preserve all relevant documentation, including transaction confirmations, account statements, and any communications relating to their Peabody Energy holdings, as such records may be relevant to establishing eligibility and calculating losses. Given that the lead plaintiff motion deadline is August 24, 2026, investors wishing to be considered for appointment as lead plaintiff should act well in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP or other qualified securities counsel to evaluate their legal rights and options before the deadline.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Peabody Energy securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c46f8225-99fd-43ae-b90f-feda2b5ec5ec
Media veteran Michael Wolf discusses Allen & Company's annual Sun Valley Conference and breaks down the mega deals that are reshaping the entertainment industry. He explains why free ad-supported content is the unsung winner of the streaming wars, and digs into the ways AI is changing the value of content.
WD-40 Company NASDAQ: WDFC has long been considered a quality investment due to its global branding power, cash flow, and capacity for capital returns. The company has a tremendous moat, claims near-100% global brand recognition, and has no competitors of merit.
WD-40 Today
$264.91 +25.49 (+10.65%)
As of 07/10/2026 04:00 PM Eastern
52-Week Range$175.38▼
$298.90Dividend Yield1.54%
P/E Ratio45.05
Price Target$305.00
The problem over the last few years has been positioning. The company’s fragmented portfolio and loss of focus led to stagnant growth in the post-COVID era and an eventual repositioning effort.
Get WD-40 alerts:
Today, WD-40 has emerged as a global maintenance powerhouse, focused on premiumization, international markets, and effective cost controls. There is risk in its above-average valuation, but its premium price is well deserved.
The asset-light model utilizes 3rd-party manufacturers and distributors, insulating it from risks, and produces high-margin results.
The strength of its model is reflected in the stock beta, which tends to run low, about 0.25x the S&P 500 as of mid-2026, revealing a low-volatility stock insulated from broad market risk.
WD-40 Company Tailwinds Strengthened in Fiscal Q3WD-40 Company had a robust fiscal Q3, with revenue growing 24% to over $195 million, nearly 1,300 basis points (bps) above MarketBeat’s reported consensus. Strength was driven by all regions and most categories, with the harvest brands the only one to decline.
The harvest brands are the company’s smallest segment, long in decline, but still a high-margin business, which is likely to remain in WD-40 Company's portfolio for the foreseeable future. Double-digit growth was seen across all geographic regions, led by 29% growth in the Americas and 24% in Asia, with strength across product lines. The critical factor was strength in the premium product lines, which draw higher margins.
Margin news was a catalyst for higher share prices. The company experienced higher input costs and increased marketing, and saw its SG&A grow as a percentage of revenue, but these negative impacts were offset by the leverage of scale and efficiency improvements, leaving gross and operating margins up on a year over year (YOY) basis. The takeaway is that a net margin of 15.5% is solid for a business of this nature, and net income grew by 44%, outpacing the 24% top-line gain.
Guidance was another catalyst, as management aggressively increased its outlook. While the revenue forecast aligned with the consensus estimate, earnings were far superior. The $6.05 low-end was more than a nickel above expectations and potentially cautious, given the trends.
Input costs are impacting the business today, but pricing actions are already in place that are expected to bear fruit early next year. There is a risk of consumer pushback, but it is minimal. Consumers are less sensitive to pricing increases than they might be because each can last for so long.
WD-40 Company Signals Confidence With Guidance Increase WD-40 Dividend PaymentsDividend Yield1.54%
Annual Dividend$4.08
Dividend Increase Track Record17 Years
Annualized 5-Year Dividend Growth7.15%
Dividend Payout Ratio69.39%
Upcoming Ex-Dividend DateJul. 17
WDFC Dividend History
WD-40 Company is a healthy capital return machine, and it signaled confidence in its outlook with a fresh $100 million share buyback authorization. Buyback activity in 2026 resulted in a 0.6% average quarterly decline, 0.4% year-to-date, a pace that will likely continue in upcoming quarters. The share count is consistently reduced, providing shareholders with improved leverage and offsetting the impact of distribution increases on cash flow.
WD-40’s dividend yield isn’t high, at about 1.7%, but it is a healthy payout, better than the S&P 500 average, and is on track for annual distribution increases. The lower yield is due in part to the firm's valuation, which is in turn driven by the payout quality.
The payout ratio is high at face value but backed up by high margins, a fortress balance sheet, and unimpeded cash flow that points to sustainability, if nothing else. The likely outcome is that WDFC sustains its modest pace of distribution growth well into the future, reaching Dividend Champion and Dividend King status over time.
Seismic Shift in WDFC Stock Price ActionThe fiscal Q3 release and guidance update triggered a seismic shift in the WDFC market. Up nearly 15% in pre-market trading, WDFC opened at a multi-year high the day after the release.
Buyers are centered in the institutional group, which has been accumulating at an aggressive $ 2-to-$1 pace over the trailing 12-month period. They own more than 90% of the stock and reflect a high degree of confidence in the cash flow and capital return outlook.
Analysts' coverage is equally bullish. MarketBeat tracks only four with current ratings, but the consensus is Buy, the Buy-side bias is 75%, and no Sell ratings are logged. More importantly, consensus price target in play is $305, still presenting upside even to the premarket price spike in WDFC shares. The likely outcome is that analyst sentiment firms up, cementing price action at current or even higher levels. With growth, outperformance, and capital return strength in place, price targets will rise over time, reinforcing the uptrend driven by corporate growth and capital returns.
Should You Invest $1,000 in WD-40 Right Now?Before you consider WD-40, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WD-40 wasn't on the list.
While WD-40 currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Verra To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Verra between February 24, 2026 and May 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 11, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verra Mobility Corporation (“Verra” or the “Company”) (NASDAQ: VRRM) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Verra’s relationship with Avis Budget Group (“Avis”), and in particular obtaining a contract extension with Avis. Further, the Company minimized concerns that major rent-a-cars could replace Verra with in-house solutions or outsourced alternatives.
On May 26, 2026, Verra issued a press release announcing a termination notice from Avis regarding its contract and accordingly lowered its 2026 full-year financial outlook. Almost one week later on June 1, 2026, the Company announced a sudden and surprising transition of its President and Chief Executive Officer David Roberts. Following this news, the price of Verra’s common stock declined dramatically.
From a closing market price of $13.08 per share on May 26, 2026, Verra’s stock price fell to $3.85 per share on May 27, 2026, a decline of about 71%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Verra’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Verra class action, go to www.faruqilaw.com/VRRM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Verra Mobility Securities Class Action Lawsuit:
What is the Verra Mobility securities fraud lawsuit about?
The lawsuit alleges Verra Mobility misled investors about the strength of its relationship with Avis Budget Group, the likelihood of a contract extension, and the risk that major rental car companies could replace Verra’s services with alternative solutions.
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Verra Mobility (NASDAQ: VRRM) securities between February 24, 2026 and May 26, 2026 may be eligible to participate if they suffered losses related to the alleged misconduct described in the complaint.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the interests of the proposed class and helps oversee the litigation. Investors seeking appointment must file a motion with the court by August 4, 2026. Investors can share in any recovery without serving as lead plaintiff.
What should investors do if they purchased Verra Mobility stock during the Class Period?
Investors should review their transaction records, preserve relevant documents, and evaluate their legal rights. Those who suffered losses may wish to consult counsel regarding participation in the lawsuit or seeking lead plaintiff status before the deadline.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Verra Mobility securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Badger Meter To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Badger Meter between April 18, 2024 and April 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 11, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Badger Meter, Inc. (“Badger Meter” or the “Company”) (NYSE: BMI) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that Badger Meter’s strong financial results reflected “ongoing favorable industry trends,” “secular growth drivers,” and “solid operating execution.” They likewise touted “strong” demand and said they were seeing “robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth,” and that Badger Meter possessed a “long runway” for growth.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Badger Meter’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Badger Meter class action, go to www.faruqilaw.com/BMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Badger Meter Securities Class Action Lawsuit:
What is the Badger Meter securities fraud lawsuit about?
The Badger Meter securities fraud lawsuit is a federal securities class action alleging that Badger Meter, Inc. (NYSE: BMI) and its executives made false and misleading statements to investors by touting "strong" demand, a "robust" order pipeline, and a "long runway" for growth while concealing that the Company's financial results were not sustainable. As the truth emerged through a series of disclosures — including disappointing Q2 2025 results and a sequential sales decline forecast on July 22, 2025, missed revenue expectations and a 6% sequential decline in utility water sales on January 28, 2026, and Q1 2026 earnings that missed consensus estimates by $0.26 per share with revenue missing by $28.58 million on April 17, 2026 — BMI's stock price dropped sharply, causing significant losses for investors.
Who may be eligible to participate in the Badger Meter class action lawsuit?
Investors who purchased or acquired Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Badger Meter securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Badger Meter employees, and others with relevant information about the Company's conduct are also encouraged to come forward.
What is a lead plaintiff, and how can I seek appointment in the Badger Meter lawsuit?
A lead plaintiff in the Badger Meter class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Badger Meter investor who purchased BMI stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.
What should investors do if they purchased Badger Meter stock during the Class Period?
Investors who purchased Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Badger Meter securities class action is August 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/BMI for more information.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7f60c456-51b6-4096-a862-d5d3beda6cc5
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Smartphone silicon content is quietly repricing. On-device AI, camera stacks and RF complexity are lifting chip dollars per handset just as the next refresh cycle arrives, and the market has already begun pricing the winners. One name in this basket is up 74.95% year to date. Another is down 19.55% over the past year. That gap is the trade.
1. Synaptics (NASDAQ:SYNA | SYNA Price Prediction): The Surprise Lead Nobody puts Synaptics on a smartphone-chip list first. They should. The company still ships touch controllers, display drivers, and wireless connectivity silicon into handsets, but the real story is the Edge AI pivot that is bleeding straight back into the phone. CEO Rahul Patel is explicit: “We are seeing accelerating activity in Physical AI and Edge AI, with increasing design wins and customer engagements.” That is exactly the content-per-device story that reprices a sleeper.
The fiscal Q3 2026 earnings report backs it up. Revenue hit $294.20 million, an 8.17% beat on non-GAAP EPS of $1.09, and management now expects full-year fiscal 2026 Core IoT revenue to grow more than 40% year over year (YoY) to over $385 million. Analysts have a $145.33 average price target against a current price near $127, with a forward P/E of 23.
If Synaptics is the surprise, the next name is the anchor of the entire on-device AI thesis. It just came off its worst handset quarter of the cycle, which is precisely why it matters.
2. Qualcomm (NASDAQ:QCOM): The Heavyweight Reset Qualcomm is the direct pipe. Snapdragon SoCs, RF and modems sit in the flagship tier of nearly every non-Apple premium phone, and the on-device AI narrative runs through this silicon. The Q2 fiscal 2026 handset report was ugly on purpose: $6.024 billion in handset revenue, down 13% YoY, hammered by memory supply constraints and Chinese OEM softness. That is the setup phase before the thesis takes hold.
Management’s own words matter here. CEO Cristiano Amon said Chinese handset revenues are expected to bottom in Q3 FY26 and return to sequential growth the quarter after. Automotive hit a record $1.326 billion, up 38% YoY, and the company authorized a $20 billion share repurchase program. Three things line up: a handset trough already telegraphed, a diversification cushion, and a buyback the size of a small semi peer.
Shares are up 9.35% year to date (YTD), trading at a forward P/E in the low double digits with a 1.89%-adjacent dividend. But the cleanest content-per-device story on this list sits in a $150 iPhone bill of materials that nobody notices until it grows.
3. Cirrus Logic (NASDAQ:CRUS): The Apple Content Escalator Cirrus Logic is a pure Apple content bet. About 92% of Q4 fiscal 2026 revenue came from a single customer, and that concentration is the feature by design. Every new controller, codec, or power IC that gets designed into an iPhone drops straight to the top line. CEO John Forsyth said the company is “developing next-generation camera controllers and a smart power IC, which represents an exciting new application space for the company.” Translation: more silicon per iPhone in the next cycle.
The numbers are already reflecting it. Q4 FY26 delivered a 59.84% EPS beat at $1.95, full-year free cash flow surged to $635.76 million (up 52.97%) and Q1 FY27 guidance of $430 million to $490 million implies roughly 13% YoY growth at the midpoint. The stock is up 25.65% YTD and trades at a forward P/E of 15 against an analyst target of $184.25.
July 16 is the Final Day to Tap Into the Lithium Boom (sponsor)
General Motors, POSCO, and 50,000+ everyday investors have already backed lithium producer EnergyX.
Here's why you should do the same before their July 16 investment deadline: lithium prices are up 75% this year, with demand projected to grow a staggering 5X by 2040.
With tech that can recover up to 3X more lithium than traditional methods, EnergyX is preparing to unlock up to 15M+ tons. Become a private-stage EnergyX investor before the July 16 deadline.
Apple content is the escalator. The next name is the elevator: same building, faster ride and every quarter the margin numbers get louder.
4. Qorvo (NASDAQ:QRVO): RF Front-End Leverage Qorvo is the RF front-end play in its most concentrated form. Every 5G/6G-capable handset needs more filters, more amplifiers, more tuning, and Qorvo’s silicon is embedded across flagship stacks. The pending merger with Skyworks has forced management to suspend guidance calls, but the standalone margin data is doing the talking.
Fiscal Q4 2026 non-GAAP gross margin expanded 670 basis points year over year to 52.6%, EPS beat consensus by 39.48% at $1.69, and management still expects fiscal 2027 non-GAAP diluted EPS approaching $7.00. CEO Bob Bruggeworth framed it plainly: “For full-year fiscal 2027, we continue to expect non-GAAP gross margin above 50% and non-GAAP diluted earnings per share approaching $7.00.”
Shares trade near $86 against a forward P/E of 13, essentially flat YTD at -0.53%. Analysts sit at $91.46 with the crowd still cautious. That is exactly the setup investors want heading into the payoff slot, because the other side of this merger has the punchline nobody is pricing.
5. Skyworks Solutions (NASDAQ:SWKS): The Payoff Skyworks is the beaten-down contrarian. Shares are down 6.24% YTD, 22.29% over the past year and 68.15% over five years, and the entire Street knows the Apple concentration story. What the Street is still underwriting is the landmark. A multi-generational design win with a leading Android OEM is expected to generate over $1.00 billion in revenue through 2030, directly attacking the customer concentration that has anchored the discount. That is the punchline.
The Q2 fiscal 2026 earnings report already shows the turn: revenue of $943.70 million beat consensus by 4.65%, non-GAAP EPS of $1.15 beat by 10.10%, and Broad Markets is expected to hit roughly 43% of Q3 sales on double-digit growth. CEO Phil Brace said “Mobile outperformed expectations on healthy demand, while Broad Markets continues to accelerate, delivering double-digit year-over-year growth driven by Wi-Fi, data center, and automotive.”
Shares trade near $60 with a forward P/E of 11 and a 4.70% dividend yield. With the pending Qorvo merger already at 81% shareholder approval, the setup combines a stated $1B Android revenue ramp, a broad markets acceleration, and a combined RF footprint the market has yet to price coherently. That is the highest-torque handset chip trade in this basket.
The Setup The upgrade cycle works as a content-per-device escalator that pays across five different silicon layers: Edge AI (SYNA), on-device compute and modem (QCOM), audio and power (CRUS), RF front-end (QRVO) and the combined RF platform after the Skyworks-Qorvo close (SWKS). One name is already up 74.95% YTD. Two are still trading below their 200-day moving averages. The gap closes when the refresh volume shows up in the September and December earnings reports.
Meet America's Newest $1b Unicorn (Sponsor) A US startup just passed a $1 billion private valuation, joining billion-dollar private companies like OpenAI and ByteDance. Unlike those other unicorns, you can invest in EnergyX right now; but only until July 16.
Over 50,000 people already have, along with global giants like General Motors and POSCO.
Here's why there's so much interest: EnergyX's patented tech can recover up to 3X more lithium than traditional methods. That's a big deal, as demand for lithium is expected to 5X current production levels by 2040. Become an early-stage EnergyX shareholder before the 7/16 investment deadline.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Applied Materials (NASDAQ:AMAT | AMAT Price Prediction) just told the Street its semiconductor equipment business will grow more than 30% in calendar 2026, an upward revision from a prior bar of 20%. That is the sound of an AI fab CapEx supercycle shifting from thesis to invoice, and the picks-and-shovel names selling into every foundry, HBM stack and gate-all-around node are the ones cashing the checks. Five stocks sit directly under that spending fire hose. Here is where the money is moving, in order.
1. Onto Innovation: The Advanced-Packaging Sleeper Onto Innovation (NYSE:ONTO) is the name most retail investors still cannot spell, but it sits at the exact chokepoint AI needs: inspection and metrology for HBM stacks, 2.5D logic and gate-all-around devices. When TSMC and SK hynix bolt an accelerator together, Onto’s Dragonfly and Atlas tools decide whether the die passes or scraps. That is process control leverage on the fastest-growing corner of the fab, well beyond commoditized deposition.
The Q1 FY26 earnings report did the talking. Revenue hit a record $291.95 million, up 9.5% year over year, with the advanced nodes business tracking roughly 25% full-year growth. Onto also locked a volume purchase agreement worth more than $240 million with a leading HBM manufacturer running through 2027. CEO Mike Plisinski flagged “the accelerating adoption of our Atlas G6 OCD system for next-generation logic and memory devices” as the tell.
The stock action agrees. ONTO closed at $321.44 on July 10 after ripping nearly 94% higher year to date and more than 212% over the past year. The analyst target sits at $369.60 with seven of seven analysts at a Buy or Strong Buy rating. The bigger surprise is what a $479 billion incumbent is telling investors about 2026.
2. Applied Materials: The Heavyweight Raising Its Own Bar Applied Materials is the broadest AI-fab exposure in the group. Deposition, ion implant, CMP, epitaxy, advanced packaging: If a wafer moves, Applied touches it. Gate-all-around transistor transitions and HBM DRAM stacking both pull disproportionate dollars per wafer, and Applied’s Precision Selective Nitride PECVD and Trillium ALD tools were built for exactly that geometry.
Q2 FY26 delivered a fourth straight beat: non-GAAP EPS of $2.86 versus $2.66 expected, revenue of $7.91 billion, up 11.4% year over year, and non-GAAP operating margin expanding to 32.1% from 30.7%. CEO Gary Dickerson bluntly raised the ceiling: “we now expect our semiconductor equipment business to grow more than 30% in calendar 2026.”
Shares reflect the move: AMAT closed at $602.50 on July 10, up 124.09% year to date. Forward P/E of 36 is not cheap, but with 28 Buy ratings against a single Strong Sell, the Street is not blinking. The next name goes narrower and hits harder on memory.
3. Lam Research: Etch, Deposition, and the HBM Stack Lam Research (NASDAQ:LRCX) owns the etch and deposition tools required to build 3D NAND and stack HBM DRAM dies without wrecking yield. Every incremental HBM3E and HBM4 layer means more Lam content per wafer. That is why the memory recovery narrative and the AI CapEx narrative converge on this ticker.
Q3 FY26 was a record quarter across the board: EPS of $1.47 beat by 7.83%, revenue hit $5.84 billion, up 23.76% year over year, and operating margin expanded to 35.0% from 33.9%. Q4 guidance calls for revenue of roughly $6.60 billion. CEO Tim Archer framed it plainly: “Lam delivered record revenue and EPS in the March quarter as AI-driven demand reshapes the semiconductor industry.”
_________________________________
What's Your Number...?Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
The stock closed at $350.33 on July 10, up 89.31% year to date and 246.66% over the last year. Analyst target is $357.77 with 29 of 35 analysts at a Buy or Strong Buy rating. Etch and deposition are the volume game. The next stock is the quality game, and it has monopoly economics.
4. KLA: The Process-Control Moat Nobody Can Bypass KLA Corporation (NASDAQ:KLAC) does one thing better than anyone: tell foundries where the defects are before a wafer becomes a $30,000 doorstop. There is no advanced node, no HBM stack and no CoWoS package being built at scale in 2026 without KLA inspection and metrology on the floor. That is the moat, and it prints margins that look like software.
Q3 FY26 revenue was $3.42 billion, up 11.5% year over year, with the Semi Process Control segment doing $3.08 billion. The kicker is profitability: TTM operating margin of 41.2% and return on equity of 95%. Capital return matched the confidence: a 17th consecutive dividend increase to $2.30 per share and a new $7 billion buyback authorization. CEO Rick Wallace called KLA “a key enabler of the AI ecosystem” across foundry/logic, memory, advanced packaging, and services.
KLAC closed at $231.52 on July 10, up nearly 82% year to date. Solid, though the real punchline is a $56 billion test company whose AI exposure just detonated.
5. Teradyne: The AI Test Kingpin Teradyne (NASDAQ:TER) tests the chips after everyone else builds them. Every accelerator, every HBM die, every networking ASIC gets validated on Teradyne automatic test equipment before it ships to a hyperscaler. Approximately 70% of Q1 revenue is tied to AI-related demand. There is no other name on this list with that level of direct AI concentration.
Q1 FY26 obliterated estimates. Revenue: $1.28 billion, up 87.04% year over year. Non-GAAP EPS: $2.56 versus $2.11 expected, a 21.15% beat. Non-GAAP operating margin expanded to 37.5% from 20.5% a year prior, and net income surged 303.36% to $398.9 million. CEO Greg Smith made the thesis explicit: “our results reflect the strength of our wafer to AI data center strategy.”
Shares closed at $359.60 on July 10, up 73.25% year to date and 264.63% over the past year. Analyst target is $423.41. Retail has noticed too: Reddit engagement spiked in mid-June with 263 upvotes and 73 comments in a single peak window on r/wallstreetbets. Robotics remains free optionality on top of the test franchise.
The Bottom Line Applied Materials raised its 2026 growth bar past 30%, KLA green-lit a $7 billion buyback, Lam printed a record quarter, Onto locked HBM into 2027, and Teradyne grew revenue 87%. That is a coordinated capex flood, well beyond a simple rotation, and the equipment vendors are the toll booths. China export controls and tariffs remain the tail risk on all five names, but with hyperscaler capex still climbing and every advanced node needing more process control per wafer, the window for reasonable entry is narrowing quarter by quarter.
If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:
Answer a Few Simple Questions.
Get Matched with Vetted Advisors
Choose Your Fit
Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)
SummaryCoreWeave's $3.1 billion HPC-backed financing attracted approximately $19 billion of demand, reinforcing institutional confidence in AI infrastructure financing.First-quarter operating cash flow reached $3.0 billion despite $6.8 billion of CapEx, supported by 71.7% gross margins and a $99.4 billion backlog.Meta Compute triggered a 14% selloff, but CoreWeave's $21 billion take-or-pay agreement protects contracted revenue through 2032.CoreWeave trades near 6.5x forward EV/Sales, well below Nebius and IREN despite stronger revenue visibility and significantly larger contracted demand. Wavebreak/iStock via Getty Images
Although the recent pullback has enhanced the risk/reward profile of CoreWeave (CRWV), the fundamental situation is not fundamentally different. Given my reassessment of the recent events, I think that the market was overreacting to the
8.23K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRWV, NBIS, IREN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Cerebras Systems (NASDAQ: CBRS) could see improved confidence around its OpenAI infrastructure ramp following its latest 200MW European data center capacity announcement, UBS analysts wrote, noting the expansion helps reduce execution risk around the company’s cloud and colocation ambitions.
UBS wrote that the additional European capacity provides incremental support for OpenAI’s first tranche deployment, an area where investors had expressed concerns given Cerebras’ position as a relatively new entrant to the cloud and colocation leasing market.
The firm added that the expansion increases confidence in OpenAI’s ramp while providing Cerebras with flexibility to pursue additional business opportunities as the sites come online over the next four to six quarters.
Cerebras announced plans to bring its first European data center capacity online by the end of 2026, with the full 200MW expected to be available by the end of 2027. UBS estimates the new capacity represents a meaningful increase from the company’s previously announced 150MW to 200MW of contracted capacity across projects in the U.S. and Canada.
Including the European expansion and previously disclosed infrastructure commitments, UBS estimates Cerebras now has visibility to approximately 410MW of announced contracted power capacity. Those commitments include Nautilus, Colovore, Digi Power X, WhiteFiber, Scale, and Bell’s 300MW facility announced earlier this year, which UBS assumes is split roughly evenly between Cerebras and CoreWeave.
The analysts wrote that having approximately 400MW of the 500MW required for OpenAI’s first two tranches effectively secured, assuming both are deployed through cloud infrastructure, supports confidence in the deployment timeline. UBS noted that OpenAI retains flexibility to deploy the second tranche through hardware deployments in its own data centers or through cloud partners.
UBS expects the second OpenAI tranche to ramp relatively quickly during the second half of 2027 and wrote that it would not be surprised to see additional agreements with large colocation providers over the coming quarters if deployment continues largely through Cerebras’ cloud platform.
The firm maintained its price target for Cerebras at $320, as shares traded hands up 8% at about $214.
UBS’s valuation is based on an enterprise value-to-sales multiple applied to 2029 estimates and discounted back to 2027. The firm uses an average multiple of around 9 times 2029 estimated EV-to-sales from compute peers and applies it to its $13.6 billion sales estimate, which it wrote could prove conservative as OpenAI and AWS deployments ramp.
SpaceX (SPCX 4.51%) has been public for less than a month, and the stock has already made a round trip, surging after its June IPO before sliding about 34% from its high to a recent price near $148. That leaves the company valued at close to $2 trillion.
For a business still losing money, that is an extraordinary price. So the interesting question isn't what the stock does next week. It's where it could reasonably sit in five years, and what would have to happen for today's buyers to be rewarded.
Let's take a look.
Image source: The Motley Fool.
What decides the outcome Almost everything about SpaceX's future comes down to three things.
The first, and by far the most important today, is Starlink. The satellite internet service crossed 10 million active customers earlier this year and generated more than $11 billion in revenue in 2025, about 61% of the company's total. Starlink is the profit center that makes the rest of SpaceX's ambitions affordable, and its growth over the next five years is key to the bull case for the stock.
Its pricing power is largely untested, though. As competition from other satellite and ground networks grows, SpaceX may eventually have to choose between adding subscribers and protecting the prices that keep Starlink profitable.
The second engine is Starship, the giant reusable rocket meant to slash the cost of reaching orbit. If SpaceX can ramp its launch cadence and drive costs down, it strengthens everything else. Cheaper launches mean more Starlink satellites, more commercial payloads, and more government contracts. But Starship is capital-intensive and still has plenty to prove.
The third is the wild card: the company's artificial intelligence (AI) and Mars ambitions. SpaceX acquired the AI start-up xAI earlier this year, and its AI segment generated $818 million or revenue and a $2.5 billion operating loss in Q1. Layer on the enormous long-term cost of a Mars program, and you have real drains on the cash Starlink throws off.
The point is that the bull case and the bear case run on the same facts. Starlink funds the ambitions, and those ambitions could either compound SpaceX's advantages or swallow its profits.
Today's Change
(
-4.51
%) $
-6.86
Current Price
$
145.30
What the numbers would have to do So put some math to it.
SpaceX generated about $19 billion in revenue over the past year, growing more than 30%. Suppose it keeps compounding at roughly that pace for five years. That would take revenue to around $70 billion by 2031, an impressive result, and probably closer to a best-case than a floor.
Now the harder part. To simply hold a $2 trillion valuation on $70 billion of revenue, SpaceX would need to earn a healthy profit on those sales, something it doesn't do today. Even at a 20% net margin, which would be excellent for a capital-heavy space and satellite business, that is roughly $14 billion in profit. Against a $2 trillion market capitalization that's still well over 100 times earnings five years out.
In other words, even a strong five years might only justify today's price, not beat it. And that is the optimistic path. If Starlink's growth slows as it saturates its wealthiest markets, or if Starship and xAI keep swallowing cash, revenue could land well short of $70 billion -- and the stock with it.
For the shares to deliver real returns from here, then, Starlink's economics have to scale even faster, or xAI and Starship have to turn from cash drains into profit engines. That is a demanding set of assumptions. It isn't impossible -- SpaceX has a habit of doing what skeptics called impossible -- but it leaves very little room for error.
So, where will SpaceX stock be in five years?
I won't pretend to know. The honest answer is that the range of outcomes is unusually wide. My best guess is that the business will be dramatically larger in 2031, and the stock still might not have done much, simply because so much growth is already priced in. That doesn't make SpaceX a bad company. It makes it a richly valued one. If I owned it, I'd keep the position small and treat the next five years as a bet on execution I can afford to be wrong about.
In a year when the artificial intelligence (AI) trade minted fortunes across chipmakers and power suppliers, one of the companies best positioned to profit from AI at scale has been left behind. Amazon (AMZN 0.73%) has been one of the megacap laggards of 2026, up only modestly while the AI names raced higher around it.
What makes that odd is that Amazon's business is arguably in its best shape in years. The stock even drew fresh attention recently when a well-known hedge fund manager was reported to have trimmed his position, adding to a sense that the market has cooled on it.
So, with the stock sitting about 12% below its 52-week high, is Amazon a bargain hiding in plain sight? Or is the market right to hesitate?
Image source: Getty Images.
The business is quietly setting records The place to look first is the cloud. Amazon Web Services, the company's most important profit engine, just reaccelerated. AWS revenue rose 28% year over year to $37.6 billion in the first quarter of 2026. That was its fastest growth in 15 quarters, and it puts the business at about a $150 billion annual pace.
A good chunk of that reacceleration is AI itself. Companies increasingly train and run their models where their data already sits, and for many of them that means AWS.
The growth is also enormously profitable. AWS generated $14.2 billion in operating income at a 37.7% margin, which is why it drives most of Amazon's profits even though it is a fraction of total revenue.
The rest of the company pulled its weight, too. Total revenue rose 17% to $181.5 billion, and operating income jumped to $23.9 billion. That worked out to an operating margin of 13.1%, a record for Amazon and a sign that years of cost discipline in retail are finally showing up.
By segment, North America revenue rose 12% to $104 billion, and the international business grew 19%, both turning a solid profit. Advertising, a high-margin business tucked inside retail, keeps growing at a double-digit clip and quietly pads those margins.
Amazon is even building a substantial AI chip business. Its custom silicon now runs at more than a $20 billion annual revenue pace and is growing at triple-digit rates, as customers hunt for cheaper alternatives to the priciest graphics processing units (GPUs).
Today's Change
(
-0.73
%) $
-1.81
Current Price
$
245.23
What's holding the stock back So why hasn't the stock followed? The short answer is spending. Amazon poured $44.2 billion into capital projects in the first quarter alone, most of it for AI infrastructure, up from $25 billion a year earlier.
That surge has all but erased the company's free cash flow, which fell to about $1.2 billion over the trailing 12 months, down from nearly $26 billion.
That is the figure that worries investors. A company famous for generating cash is suddenly generating almost none. The bet is that today's spending builds the data centers that power tomorrow's AWS growth. But that payoff takes years, and the timing is never guaranteed.
Still, I think the trade-off looks reasonable. The spending is a choice, not a symptom of a struggling business. AWS is reaccelerating, retail margins are improving, and the chip business gives Amazon a second way to profit from AI.
Amazon has made this kind of bet before, too. It spent heavily to build AWS and its logistics network years ago, and both turned into enormous profit engines once the investment cycle passed.
And the price is fair. At about $244 as of this writing, Amazon trades at roughly 29 times earnings. That isn't the bargain-bin multiple its underperformance might suggest, but it's a reasonable price for a business growing profits at this rate, and a discount to where the stock has often traded in the past.
So is Amazon a bargain? Not a screaming one. But I think it's good value here, and the setup is appealing: a market-leading business performing well on several fronts, temporarily out of favor because it is investing heavily for the future.
Personally, I'd be comfortable buying on this weakness. I'd just go in knowing that the heavy spending, and the pressure it puts on free cash flow, is likely to continue for a while. For patient investors, the laggard may turn out to be the opportunity.
Advanced Micro Devices (NASDAQ: AMD) could be headed for a significant correction toward $335 if a key technical support level breaks, according to a TradingView analysis.
In a July 9 TradingView post, the analyst identified AMD’s daily 50-day moving average (MA) as the critical trigger level.
If that support fails, the stock could decline toward its 200-day moving average (MA200), projected near $335, with the move potentially unfolding around August 11, 2026.
Notably, AMD has been one of the semiconductor sector’s strongest performers this year, gaining over 150% in 2026 and trading at $557 as of press time after reaching highs above $560.
The analysis notes that while AMD continues to post higher highs on the daily chart, its Relative Strength Index (RSI) has been forming lower highs since late April.
This bearish divergence is often viewed as a sign that bullish momentum is weakening despite rising prices.
A similar pattern emerged after AMD’s late-2025 rally, when weakening RSI momentum preceded a break below the MA50 and a prolonged correction.
AMD stock fundamentals The current setup follows an even stronger advance, with AMD rising about 213% from its March 2026 lows compared to roughly 248% during the previous rally.
According to the analysis, the MA50 remains the key level to watch. AMD has repeatedly held above the trend line despite several pullbacks, but a decisive breakdown could trigger a deeper retracement.
In that scenario, the stock would likely seek support at its MA200, which the chart projects near $335.
The bearish technical setup emerges despite AMD’s strong business performance. The company reported first-quarter revenue of $10.3 billion, up 38% year-over-year.
In comparison, data center revenue surged 57% to a record $5.8 billion, driven by demand for EPYC server processors and AI accelerators.
AMD has also guided for roughly $11.2 billion in second-quarter revenue, with earnings scheduled for August 4. The timing is notable because the projected weakness would begin shortly after that earnings event, making the report a potential catalyst for either validating or invalidating the bearish setup.
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
Ask the question "Could this stock be a millionaire-maker?" about most trillion-dollar companies, and the honest answer has to be "Probably not."
Ask it about Nvidia (NVDA +3.90%), whose market cap of roughly $4.7 trillion makes it the most valuable company on the planet, and the answer gets more interesting: Yes, it still can -- but you'll have to bring a lot of cash to the table.
Let's be blunt about the size problem, because it's the whole story. To turn a $10,000 stake into $1 million, Nvidia would need to rise by around 100-fold. Over the past 10 years, it has more than done that. But for a company that is now already worth more than the entire German stock market, repeating the trick would imply a market cap somewhere north of $470 trillion -- larger than every public company on Earth combined today. That is not going to happen in one lifetime, and no amount of AI-related enthusiasm changes the arithmetic.
Image source: Getty Images.
So the millionaire path here isn't leverage. It's the size of your commitment. A patient investor who puts $200,000 into Nvidia and watches it quintuple over a decade -- a demanding result, but not a fantastical one for a dominant franchise -- would arrive at a seven-figure holding. The stock can still make you rich. It just asks you to already be fairly wealthy to start with, or to invest heavily and wait a long time.
Today's Change
(
3.90
%) $
7.90
Current Price
$
210.68
What Nvidia is becoming Here's the part I find more telling than any growth chart. Nvidia is no longer just selling chips; it's financing the ecosystem that buys them. The company has committed up to $100 billion to OpenAI's infrastructure build-out, is investing $2 billion in optics maker Coherent, another $2 billion in cloud provider Nebius, and struck long-term U.S. manufacturing deals with Corning and data center operator Iren.
To me, that makes Nvidia more of a kingmaker, closer in spirit to an underwriter of an entire industry than to a moonshot. It's a durable, defensible position. It is also, almost by definition, not the profile of a stock that is going to multiply even 50-fold from here.
Where the higher-leverage bets actually live If your goal as an investor is to find a stock with the potential to deliver a lottery-ticket outcome -- one where a relatively small initial position can eventually change your life -- Nvidia is the wrong pick. That asymmetry was largely captured by people who bought a decade ago. The higher-torque opportunities now tend to live in the smaller suppliers Nvidia depends on: the optics, power, and cooling names, and the still-private challengers that Nvidia itself is funding.
I think Nvidia remains a good choice for a foundational portfolio holding, and patient owners of the stock will likely do well. But be honest about the assignment: This is a compounding blue chip now, not a rocket. Size your position for steady wealth-building, and hunt elsewhere if what you truly want is explosive, high-risk upside potential.
PepsiCo Inc (PEP) released its 8-K filing on July 9, 2026, reporting significant achievements in its second-quarter results. The company demonstrated strong gro
Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/acquired products, especially from Seagen, are driving robust 20%+ growth. Seagen's acquisition is reshaping PFE's growth, with Padcev leading oncology momentum and a strong cost savings program underway.
Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious stance in volatile markets. PFE offers an attractive opportunity to offset AI-related risks within a broader portfolio context.
Palantir is rated a buy, driven by accelerating growth, expanding margins, and a misunderstood business model with a durable moat. PLTR delivered 85% YoY revenue growth, a 60% adjusted operating margin, and a Rule of 40 score of 145, outpacing software peers. Valuation is at the low end of the historical range, with PLTR trading at 81.4x P/E NTM but offering superior growth and profitability versus winners like DDOG and SNOW.
Eli Lilly (LLY 2.30%) is in a league of its own. It's the largest healthcare company in the world by market cap, with the No. 2 company (Johnson & Johnson (JNJ 0.82%)) barely over half as big. Lilly's shares have more than quintupled in value over the last five years.
But should you buy Eli Lilly stock now? Here's my honest take.
Image source: Getty Images.
Business is booming Make no mistake about it: Lilly's business is booming. The company's revenue soared 56% year over year in the first quarter of 2026 to $19.8 billion. Its adjusted earnings per share skyrocketed 156%.
Much of this growth is due to Lilly's GLP-1 franchise. Sales for Mounjaro, which is marketed in the U.S. for treating type 2 diabetes (T2D) and for both T2D and weight loss outside the U.S., jumped 125% year over year to $8.7 billion. Sales for Zepbound, the drug's U.S. brand for weight loss, increased 80% to nearly $4.2 billion.
Those numbers are so staggering that they make it easy to overlook Lilly's other success stories. For example, sales for eczema drug Ebglyss vaulted 141% higher in Q1 to $145 million. Another autoimmune disease drug, Omvoh, generated more than twice the sales in the latest quarter ($80 million) than it did in the prior year period. Blood cancer therapy Jaypirca's sales increased 79% year over year to $165 million.
Lilly recently won U.S. regulatory approval for its new GLP-1 pill, Foundayo. Analysts expect the drug to rake in full-year sales of around $1.6 billion. RBC Capital projects peak annual sales of a whopping $36 billion.
More good news could be on the way. Lilly's pipeline features 42 programs in late-stage clinical studies. The big drugmaker's buying spree, with the acquisitions of Ajax Therapeutics, Centessa Pharmaceuticals, 4E Therapeutics, and Kelonia Therapeutics, is further bolstering its pipeline.
Today's Change
(
-2.30
%) $
-27.99
Current Price
$
1,188.96
The bear case against Lilly Given all those positives, it might seem like buying Lilly's shares would be a no-brainer. However, there is a bear case against Lilly that investors shouldn't ignore.
Valuation stands at the top of the list. The big pharma stock trades at 33.4 times forward earnings. Its price-to-earnings-to-growth (PEG) ratio, which factors in analysts' earnings growth projections over the next five years, is 1.57. While that isn't a ridiculously high ratio, it suggests Lilly is still priced at a premium despite its robust growth prospects.
Another issue is that Lilly's fortunes hinge significantly on its GLP-1 drugs -- and competition is intensifying. Novo Nordisk (NVO +1.25%) has a new oral version of its weight-loss drug, Wegovy, on the market. The company's CagriSema, which is in late-stage testing, could challenge Lilly's Zepbound. Amgen (AMGN 0.02%), Pfizer (PFE 0.33%), Roche (RHHBY 0.23%), and Viking Therapeutics (VKTX 5.37%) also all have promising weight-loss therapies in development.
In the meantime, Lilly has been forced to slash Mounjaro prices in China. The company cut prices to secure inclusion in China's state-run health insurance program. Speaking of China, the U.S. House of Representatives Select Committee on China is investigating Lilly's clinical drug trials in the country. In particular, the committee is concerned about Lilly's efforts involving Chinese military hospitals and in the Xinjiang region, where the Chinese Communist Party is accused of conducting a genocide of Uyghur Muslims.
To buy or not to buy? So, should you buy Eli Lilly stock? I have a nuanced answer.
Lilly is, without question, one of the world's best pharmaceutical companies. It's a leader in multiple markets, notably the weight-loss market, which could reach $150 billion by 2035. Despite its premium valuation and other risks, I think that this stock is a good pick for long-term investors.
However, I suspect Lilly's share price could pull back further, creating an even better buying opportunity. That's what has happened several times in the past when the stock hit a record high.
I could be wrong, though. Perhaps the best approach is to buy a partial position in Lily and add to it later (perhaps after the company reports its second-quarter results on July 30, 2026). With a long-term growth trajectory like Lilly's, easing into a full stake could be a profitable strategy.
Cybersecurity has been important for years, but its significance is about to expand thanks to artificial intelligence. Every AI model, chatbot, and physical AI requires digital safeguards to deter hackers. Furthermore, hackers are using AI to penetrate more systems, creating the need for larger cybersecurity budgets.
This core thesis is part of the reason why Palo Alto Networks (PANW 3.67%) has surged by almost 80% year-to-date. While the pieces are coming together for sustained revenue growth, the current rally may be a bit overdone.
Image source: Getty Images.
Investors can already see the impact of AI Palo Alto Networks' fiscal 2026 third-quarter results pointed to meaningful revenue acceleration. Total sales increased by 31% year over year, compared to a 15% year-over-year increase in the previous quarter.
Today's Change
(
-3.67
%) $
-12.40
Current Price
$
325.91
Recent acquisitions of CyberArk and Chronosphere contributed to elevated growth rates, but Palo Alto Networks' underlying business still exhibited more growth than usual. Its annual recurring revenue (ARR) from next-generation security was up by 60% year over year. The total ARR reached $8.1 billion, with $1.6 billion of that coming from the acquisitions.
Guidance implied $3.35 billion in fiscal 2026 Q4 revenue, which would be an 11.7% sequential growth rate. Year-over-year growth rates are more attractive, but sequential growth rates factor in the recent acquisitions. Palo Alto Networks also expects to close out the year with up to $8.95 billion in ARR from next-generation security solutions, guidance that offers meaningful revenue visibility.
The valuation is hard to justify Palo Alto Networks has flipped the switch and is firmly back to being a growth stock. The period of gradually decelerating revenue growth rates appears to be over, but a high valuation still looms over the company.
Every key valuation metric you can consider leaves a bit to be desired. A P/E ratio just above 300 leaves very little room for error, and a PEG ratio that's approaching 6 also indicates the stock is overvalued. The company's price-to-sales ratio has almost doubled over the past few months and currently sits at 24 times sales.
Artificial intelligence is a multiyear tailwind that should propel Palo Alto Networks' revenue and profits. However, a lot of that success has already been priced into the stock at current levels. The cybersecurity stock recently endured a 10% dip, so more investors are noticing the high valuation.
Still, the stock is worth monitoring. Dips are valuable buying opportunities for patient investors. It's hard to question Palo Alto Networks' fundamental growth and its positioning amid a big tailwind, but the valuation needs some work.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The State Street Utilities Select Sector SPDR ETF (XLU) has long been viewed as a defensive investment, preferred by investors seeking stable cash flows, consistent dividends, and lower volatility. Since the fund’s inception in 1998, the ETF has grown to $23.65 billion in assets under management while maintaining a low 0.08% expense ratio. Holdings consist of 35 of the largest utility companies in the S&P 500, providing investors with broad exposure to the sector.
Top holdings include names like NextEra Energy (NEE), Duke Energy (DUK), Constellation Energy (CEG), and Vistra (VST) – all companies that are well positioned to benefit from the growing electricity demand created by AI data centers.
As technology companies continue to invest hundreds of billions of dollars in new AI infrastructure, utility companies that supply the power needed to operate these facilities could emerge as some of the industry’s most overlooked beneficiaries.
A Utility ETF Built for Stability XLU tracks the Utilities Sector Index, providing investors with exposure to companies involved in electricity generation, transmission, distribution, and renewable power production.
Historically, the sector has been viewed as a safe haven during periods of heightened market uncertainty due to its relatively predictable earnings and consistent dividends. The fund maintains a current annualized beta of 0.61, with upside and downside capture that has historically been muted. Additionally, XLU has maintained 26 years of dividend payments, with a current trailing-twelve-month yield of 2.64%.
While stability has traditionally come at the expense of rapid growth, the introduction of AI has created a new catalyst for funds like XLU. According to research from Goldman Sachs, by 2030, AI is expected to increase data center power demand by 165%. This is supported by research from Deloitte, acknowledging that from 2024 to 2035, demand for AI data centers is expected to increase fivefold.
AI Runs on More Than Just Semiconductors When investors think about artificial intelligence, companies like Nvidia (NVDA), Microsoft (MSFT), and Amazon (AMZN) usually are the first that come to mind. However, every AI model, cloud platform, and AI agent ultimately relies on a tremendous amount of electricity.
Training and operating these large language models (LLMs) require thousands of high-performance GPUs running 24/7 inside massive data centers. As such, these facilities require far more electricity than traditional infrastructure due to the intensive computing requirements and cooling systems.
Major technology companies continue to invest aggressively in AI Infrastructure. Collectively, Microsoft, Amazon, Google, and Meta have committed hundreds of billions of dollars toward expanding data center capacity over the next several years.
_________________________________
What's Your Number...?Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
That investment is already translating into higher demand for electricity.
Why XLU Could Benefit Many of XLU’s holdings are working to expand generation capacity, modernize infrastructure, and strengthen the electric grid to support this growing demand.
Two holdings with direct AI upside include:
NextEra Energy (NEE) – the largest holding in XLU and one of North America’s largest producers of wind and solar power. As hyperscaler data centers seek additional electricity to meet AI-driven demand, NextEra’s expanding renewable generation and transmission infrastructure position it to benefit from the sector’s long-term growth.
Constellation Energy (CEG) – operates the nation’s largest fleet of nuclear power plants, providing reliable, around-the-clock carbon-free electricity. Dependable baseload generation has made the company an increasingly important partner for technology companies looking to secure long-term power supplies for AI data centers.
Additionally, unlike many AI stocks trading at premium valuations, utilities offer investors exposure to the trend through businesses with established cash flows, solid dividend yields, and more attractive multiples. The valuation multiples for XLU are included in the table below.
Price/Earnings 18.82x Price/Book 2.14x Price/Sales 2.71x Price/Cash Flow 8.15x Final Thoughts Utilities have long been a preferred allocation for defensive investors seeking stable cash flows, consistent dividends, and lower volatility. However, AI may be changing this perception.
As AI infrastructure continues to be built out, the need for energy increases.
In the traditional sense, XLU is not an AI ETF; however, for investors looking to diversify beyond the market’s obvious winners, the fund offers exposure to the infrastructure making the AI revolution possible. Sometimes the most compelling investment opportunities aren’t found in the companies building the technology, but in those quietly supplying the power behind it.
If You’ve Been Thinking About Retirement, Pay Attention (sponsor) Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance, and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor. Here’s how:
Answer a Few Simple Questions.
Get Matched with Vetted Advisors
Choose Your Fit
Why wait? Start building the retirement you’ve always dreamed of. Get started today! (sponsor)
InterDigital maintains a stable, de-risked smartphone licensing base, complemented by a $0.70/share quarterly dividend and ongoing buybacks. IDCC's annualized recurring revenue grew 13% to $567.2M, with smartphone ARR up 18% and significant CE/IoT/Auto diversification offsetting smartphone timing declines. Margins are compressed near-term due to LG revenue-sharing and IP enforcement costs, but management reaffirms full-year guidance and expects normalization post-2026.
SummaryCoreWeave is the leading neocloud operator, trading at a discounted 11.9x forward EV/EBITDA versus the sector median of 15x.CRWV's $99.4B backlog is 98% under five-year take-or-pay contracts with major hyperscalers, supporting robust forward revenue visibility.Backlog risk is real; however, thanks to heavy CapEx, CRWV provides quality and dominance for their clients. Realization of contracts is key.I estimate significant, 250%+ upside from current price levels until the end of 2027 based on margin expansion and backlog conversion, as well as improvement.Erik Isakson/DigitalVision via Getty Images
Editor's note: Seeking Alpha is proud to welcome Krzysztof Bogdanski as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock
1 Follower
Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRWV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Members of the U.S. Congress buying a stock usually isn't a big deal. It happens all the time. However, some transactions by politicians are noteworthy -- especially for investors.
That's the case with two recent transactions involving Space Exploration Technologies (SPCX 4.51%), better known as SpaceX. There's bipartisan interest in SpaceX, with Rep. Dan Meuser, R-Penn., and Rep. Gil Cisneros, D-Calif., becoming the first members of Congress known to have disclosed investments in the space stock. Is this a bullish signal for other investors thinking about buying SpaceX?
Image source: Getty Images.
Not just any congressional trades Rep. Meuser disclosed a purchase of SpaceX stock on June 15, 2026, only three days after the company's record-setting IPO. The congressman's regulatory filing revealed that his dependent child bought between $15,001 and $50,000 of the stock. Rep. Cisneros bought between $1,001 and $15,000 of SpaceX shares on June 18.
There are no yellow flags with either of these transactions, by the way. Both members of Congress complied with disclosure requirements. Neither has been accused of trading on information that isn't public or violating any law. Cisneros issued a statement to CNBC emphasizing that he doesn't personally manage his investments. The California Democrat said that he and his wife use "outside financial advisors who have a fiduciary responsibility to maintain a diverse portfolio."
The interesting thing about these two representatives, though, is their committee assignments. Meuser is on the House Financial Services Committee, which oversees securities and exchanges. Cisneros serves on the House Armed Services Committee, which has jurisdiction over the Department of Defense.
SpaceX has around $22 billion in contracts with U.S. government, with the Defense Department ranking as one of its fastest-growing government customers. NASA is the company's largest federal customer, with roughly $15 billion in contracts.
Today's Change
(
-4.51
%) $
-6.86
Current Price
$
145.30
What history shows In 2004, Alan Ziobrowski, Ping Cheng, James W. Boyd, and Brigitte J. Ziobrowski published a detailed analysis of stock investments made by U.S. Senators between 1993 and 1998. They found that a portfolio that copied senators' buy transactions beat the market by 85 basis points per month, while a portfolio that mimicked their sales beat the market by 12 basis points per month.
Importantly, though, that study was based on data before the implementation of the Stop Trading on Congressional Knowledge (STOCK) Act of 2012. This legislation banned members of Congress, as well as the President, Vice President, and all federal employees, from using nonpublic information to which they have access through their official positions for personal financial profit. The STOCK Act also mandated financial disclosures.
You'll sometimes see reports about individual members of Congress achieving outsize returns from their investments. However, a 2022 analysis by William Belmont, Bruce Sacerdote, Ranjan Sehgal, and Ian Van Hoek concluded that "House and Senator stock returns are consistent with random stock picking."
Similarly, Vishaal Baulkarna and Pawan Jain published research in 2025 analyzing two exchange-traded funds (ETFs) that sought to replicate trades of members of Congress. They determined that "neither ETF significantly outperforms the market on a risk-adjusted basis."
The Unusual Whales 2025 Congress Trading Report found that only 32.2% of congressional portfolios outperformed the S&P 500 (^GSPC +0.42%) last year. The reported stated, "This success rate effectively mirrors the professional financial world." The conclusion: "In 2025, Congress proved to be no better than the average money manager."
Not necessarily a bullish signal The bottom line for investors considering SpaceX stock is that congressional buys aren't necessarily a bullish signal. At least on an overall basis, members of Congress haven't consistently beaten the market with their stock picks. Buying SpaceX just because two representatives did, therefore, probably isn't a smart move.
Apple on Friday accused OpenAI of stealing trade secrets as it seeks to build its own hardware for ChatGPT, a major rupture in a partnership between the iPhone maker and the artificial intelligence company.
Ten years ago, Nvidia (NVDA +4.03%) was known mostly for making graphics cards that gamers cared about. Adjusted for its later stock splits, the shares traded for about $1.28 in the summer of 2016.
Today they change hands near $204. A $10,000 investment back then would have bought roughly 7,800 shares -- worth about $1.6 million now. That is a gain of nearly 160-fold, from a single, unglamorous chip stock.
The number is staggering. But the more useful question for investors today isn't how big the gain was. It's what produced that gain, and where anything close might come from now.
Image source: Nvidia.
What turned $10,000 into a fortune For most of the past decade, Nvidia's rise rested on a bet that proved enormous: that its graphics chips, originally built to render video games, were also the ideal engines for artificial intelligence (AI).
That bet paid off spectacularly. When the AI boom arrived, the parallel computing power packed into Nvidia's chips made them the default hardware for training and running AI models. Demand exploded, and Nvidia had a years-long head start on the software and networking wrapped around those chips.
Additionally, Nvidia's software has kept customers loyal. Developers built their AI systems on its programming tools over many years, and that installed base makes the switching costs high for its customers.
Nvidia is no longer just a chip company, either. It now sells entire systems that bundle processors, networking, and software, deepening its hold on the data center. Together, those advantages have let it hold both its share and its pricing even as competitors piled in.
Its dominance, of course, is clear by its financials. In the fiscal first quarter of 2027 (the period ended April 26, 2026), Nvidia posted record revenue of $81.6 billion, up 85% year over year. Its data-center business alone brought in $75.2 billion, up 92%.
And the company's profit growth has been extraordinary. Earnings have compounded so quickly that the stock, up nearly 160-fold, has actually kept pace with the underlying business rather than racing far ahead of it. This is clear from the stock's price-to-earnings ratio of just 31 today.
That last point matters. A 160-fold gain sounds like pure mania. But it was largely earned, not just imagined.
Today's Change
(
4.03
%) $
8.18
Current Price
$
210.96
Can anything like it happen again? Here is the hard truth for anyone hoping to catch the next Nvidia in Nvidia. The math simply won't allow a repeat.
Nvidia is now worth about $4.9 trillion, one of the most valuable companies on Earth. Turning that into another 160-fold gain would require a market value of several hundred trillion dollars -- larger than every stock market on the planet combined. It isn't going to happen.
So the honest expectation is far more modest. From here, Nvidia's returns will track its business, not another once-in-a-generation rerating stacked on top of it.
The good news is that the business still looks like it's firing on all cylinders. Data-center revenue is still growing fast, and guidance calls for revenue of about $91 billion in the current quarter, another step up. The giant cloud providers that buy most of its chips are still expanding their AI budgets, which underpins demand. The newest Blackwell chips are ramping. And despite the enormous market value, the stock isn't priced like a bubble. It trades at about 31 times trailing earnings and closer to 20 times expected earnings over the next 12 months.
Of course, there are real risks. The AI build-out could slow, big customers are designing their own chips, and a business this cyclical rarely grows in a straight line. A stock that has come this far already has plenty of optimism baked in.
So what's the takeaway from that $1.6 million?
Mostly, it's a lesson in what patience plus a genuine technology shift can do -- and a reminder not to anchor on the past. The investor who turned $10,000 into a fortune did it by owning a business that grew into something the market couldn't yet imagine. Nvidia can still be a fine investment from here, and I wouldn't bet against it lightly. But anyone hunting for the next 160-bagger should probably be looking somewhere smaller, earlier, and far less famous.
By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Ford's all-important EV pickup truck has donned camouflage during public outings. The sneaky attire includes a QR for a hidden website landing page. Ford Ford has been camouflaging its coming $30,000 EV pickup during public testing. Turns out, the going-out attire is intentionally revealing.
Photos and videos of the disguised truck have circulated widely online in recent weeks. And some of Ford's wraps have obscured the truck's body lines with a jumble of dogs, sailboats, soccer balls, heart emojis — and tiny QR codes.
Scanning one sends curious onlookers to an official Ford webpage that declares, "Congrats, You Spotted a Unicorn." There, the automaker shows clearer footage of the pickup undergoing snow testing and moving through production, while inviting visitors to sign up for updates.
"Chances are, you saw something on the road that piqued your interest, and you're here because you're curious," Alan Clarke, Ford's vice president of advanced development projects, says in a video at the top of the site. "This website will be your exclusive insight into our progress."
The camouflage is doing two jobs at once: concealing the big-bet truck's final shape and helping Ford build an audience before it officially pulls back the covers.
An EV recharge
Ford discontinued the all-electric F-150 Lightning after sales never reached the company's 150,000 unit-per-year goal. Scott Olson/Getty Images There is plenty riding on the truck underneath.
The so-far unnamed EV (though rumors and patent applications suggest Ford may be resurrecting the Ranchero nameplate) is scheduled to reach customers next year. It's a big reset for the legendary automaker.
Around 2020, Ford had high hopes for its first generation of mass-market EVs, including the F-150 Lightning, a full-size electric pickup that started at mid-$50,000. Ahead of its launch, Ford touted nearly 200,000 reservations and set a goal of eventually building 150,000 electric trucks a year.
Sales peaked in 2024 at 33,510 vehicles, falling far short of Ford's early ambitions. The automaker ended production of the original Lightning in late 2025 and recorded $19.5 billion in charges tied to its broader EV restructuring.
As its initial EV plans faltered, Ford assembled a roughly 350-person California skunkworks team led by Clarke to develop a cheaper and more efficient generation of electric vehicles, called the universal EV platform. The group focused on faster manufacturing, more aerodynamic designs, and dramatically fewer parts.
The camouflaged pickup will be the first test of that strategy. Ford says it can build up to eight different vehicles on the same battery infrastructure.
A tricky EV market with new contenders
Ford's EV comes as it tries to ward off Chinese EV-makers. Other American startups, like the Slate Truck pictured above, are entering the fray as well. Ben Shimkus/Business Insider Ford's lower-cost EV push is taking shape as a new crop of challengers reaches the US market.
Slate, a Jeff Bezos-backed startup, told Business Insider that the first units of its $24,950 electric pickup will reach customers this year. Fiat has also brought the sub-$15,000 Topolino to the US, although the tiny EV is closer to a golf cart than a daily driver.
And the greatest threat may be overseas.
BYD became the world's largest seller of battery-electric vehicles last year, reaffirming the pressure Chinese automakers are placing on established car companies. Ford CEO Jim Farley has repeatedly praised Chinese EVs for their technology, affordability, and build quality.
When Ford unveiled its Universal EV Platform in 2025, Farley framed the project as a response to competitors attacking the industry from several directions.
"We knew that the Chinese would be the major player for us globally, companies like BYD, new startups from around the world," he said in 2025. "Big technology has their ambition in the auto space. They're all coming for us, legacy automotive companies."
Read next
Ben Shimkus You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Ben Shimkus is a reporter for the Business News desk. He writes about cars, transportation, retail, and jobs. Ben's reporting has appeared in Rolling Stone, The Verge, Automotive News, USA Today, AutoBody News, LGBTQ Nation, TopSpeed, and Out Magazine. He's also held staff writing positions at The U.S. Sun and the Daily Mail. He graduated from NYU with a Master's in journalism in 2024. Email Ben at [email protected] or message him privately on Signal at bshimkus.41.
There have been few happier investors than Intel (INTC 2.40%) and AMD (AMD +2.13%) investors in 2026. If you purchased shares at the start of 2026, the returns have been phenomenal. Intel's stock essentially tripled, while AMD's stock is up around 140%. Those are fantastic results, but both stocks have shown weakness in the past few days.
Since the calendar flipped to July, there has been heavy selling pressure on these two names, and AMD stock has plunged more than 10% while Intel is down 20%. That's a major sell-off in a short time frame, but does that mean it's time for investors to panic and sell the stock? Or is this a prime buying opportunity? Let's find out.
Image source: Getty Images.
The turnaround is still ongoing for these two AMD and Intel have a theme in common: They're both turnaround plays. Both AMD and Intel have lost to their chief rivals in recent years, and the market is betting on a major turnaround.
AMD is trying to gain ground on Nvidia (NVDA +4.03%) in the GPU marketplace. The biggest growth area for this product line is in the data center space, where Nvidia has outright dominated AMD. However, there were hopes that AMD could gain some ground back on Nvidia.
During the first quarter, AMD's data center division grew 57% year over year to $5.8 billion in revenue. That's a notable improvement over previous quarters and a strong result overall, but it's just not Nvidia. During Nvidia's Q1, its data center division generated $75.2 billion in revenue, rising 92% year over year. So not only is Nvidia nearly 15 times larger, but it's also growing far faster.
Today's Change
(
2.13
%) $
11.62
Current Price
$
558.34
It doesn't look like AMD is doing anything special versus the undisputed industry leader, Nvidia, so I have doubts about AMD's strength.
Meanwhile, Intel is chasing competitors on two fronts. For its chip division, it's actually competing against AMD. However, the bigger focus for Intel has been its chip foundry business, which competes against Taiwan Semiconductor Manufacturing (TSM 0.55%) During Q1, Intel's foundry division grew revenue by 16% to $5.4 billion. Once again, it was outperformed by TSMC, which saw revenue of $35.9 billion, rising 41% year over year.
Today's Change
(
-2.40
%) $
-2.70
Current Price
$
109.84
The market expects Intel and AMD to be incredible turnaround plays, but the reality is that the companies that have been dominating them in recent years are still far superior. To make matters worse, each is expensively valued.
Expectations priced into the stocks are too high Looking at the valuations of Intel and AMD also reveals another key factor: All of the turnaround that really hasn't occurred yet has already been priced into the stocks. AMD trades for 70 times forward earnings, while its rival Nvidia trades for 22.8. The same goes for Intel, which trades for 100 times forward earnings compared to TSMC's 27.5.
TSM PE Ratio (Forward) data by YCharts
For these two to grow into their valuations and trade at similar levels to their rivals, Intel must increase its earnings fourfold beyond 2026's projections. AMD is a little less aggressive, but it still must triple its earnings beyond 2026's predictions. That's a monster performance, and with its rivals continuing to grow their earnings and revenue at a remarkable pace, the bar will keep moving higher for the companies to reach a reasonable valuation.
As a result, I think selling Intel and AMD in favor of their rivals makes the most sense. These two stocks have run up a ton and likely have gotten far too ahead of themselves. Meanwhile, TSMC and Nvidia trade at attractive valuations, and I think investors will be far more satisfied with the long-term returns of these two than with AMD and Intel.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
SummarySSR Mining Inc. offers a compelling buy opportunity, trading at a 0.76x P/NAV discount post-Çöpler sale and portfolio transformation.Çöpler and Hod Maden exits have eliminated major jurisdictional risks, unlocking $1.5 billion in cash and streamlining the asset base for re-rating.Management is returning $800 million to shareholders via buybacks and a reinstated dividend while maintaining a robust $1 billion net cash buffer.With normalized AISC dropping and Q2 2026 marking the first clean quarter, SSRM presents 15–20% near-term upside, with potential for 50%+ if gold prices hold. pidjoe/iStock via Getty Images
SSR Mining Inc. (SSRM) is a Denver-based precious metals producer with gold, silver, lead, and zinc assets across Colorado, Nevada, Saskatchewan, and Argentina. It has recently had a valuable exit from Türkiye, where a 2024 accident has, paradoxically, set the stage for what may
135 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
In the age of artificial intelligence (AI) infrastructure, Micron Technology's (MU 1.05%) plan to invest more than $250 billion in U.S. fab expansions marks an aggressive escalation. This capital outlay aims to scale the company's DRAM manufacturing while laying the groundwork for higher-volume high-bandwidth memory (HBM) production.
By deepening production at domestic facilities, Micron is increasingly positioned to capture a larger share of the AI memory supercycle amid fierce competition from SK Hynix and Samsung.
Image source: Micron Technology.
Secular AI demand is mitigating cyclicality in the memory market Micron's decision to increase investment in manufacturing may seem counterintuitive because memory markets have historically moved in tandem with PC and smartphone cycles. However, hyperscalers like Microsoft, Alphabet, Amazon, and Meta Platforms have demonstrated an insatiable appetite for AI infrastructure, including advanced memory chips.
In particular, HBM stacks require large quantities of advanced DRAM wafers and sophisticated packaging. These are the areas that Micron's investments are targeting. Scaling output supports Micron's long-term goal of producing 40% of total DRAM domestically. The vision is to create a more durable growth trajectory, enabling the company to close the market-share gap with overseas rivals.
Today's Change
(
-1.05
%) $
-10.39
Current Price
$
981.25
Micron has been investing in U.S. manufacturing already In New York, the company is building a complex with up to four fabs focused on high-volume DRAM production. Meanwhile, in Idaho and Virginia, Micron is investing in further R&D to accelerate product development and modernize existing operations.
By doubling down on existing infrastructure with this new multiyear build-out, Micron is quietly creating an end-to-end domestic ecosystem spanning wafer fabrication through advanced packaging. This playbook rivals the integrated operations long enjoyed by SK Hynix and Samsung in Asia.
Micron's progression over the next several years should transform earlier piecemeal investments into a more cohesive platform purpose-built for sustained leadership in both DRAM and AI-optimized HBM, directly fueling the company's ongoing ascent throughout the AI infrastructure era.
Adam Spatacco has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Micron Technology, and Microsoft. The Motley Fool has a disclosure policy.
Micron Technology (MU 1.05%) has emerged as one of the top AI stocks. It's up by more than 700% over the past year, thanks to strong demand for its memory and storage products from AI data centers. Those facilities need huge volumes of Micron's chips to efficiently handle AI workloads, but a new wave of products may need such chips even more.
During the company's fiscal 2026 third-quarter call on June 24, CEO Sanjay Mehrotra told investors that humanoid robots are a much more promising opportunity for Micron than AI data centers. That may sound hard to believe right now, especially since Micron more than quadrupled its revenue year over year thanks to data center sales. However, the premise is worth exploring.
Image source: Getty Images.
A multi-decade memory demand cycle Some investors have shied away from the semiconductor trade due to the industry's cyclical history. The general concept is that at various points, rising demand for a particular type of chip leads to a shortage, which drives prices up.
The chipmakers supplying those products book higher profits, but they also rush to boost their production capacity so that they can sell as many of those chips as possible. "Rush," however, is relative. It can take a couple of years to get new chip fabrication facilities online.
Today's Change
(
-1.05
%) $
-10.39
Current Price
$
981.25
Eventually, more supply arrives, cutting into chipmakers' pricing power. Then, frequently, total demand slides, and the chipmakers are stuck with inventory gluts. But they have to get rid of their older models to make room for new chips with better technological features. The solution is price cutting, which results in further reduced revenues and even tighter margins.
Memory chips in particular have been subject to these cycles, as the technology has largely been commoditized. There's not an enormous amount of variation between the products made by Micron and its peers.
Bullish investors view Micron as being in the middle of a multiyear up cycle driven by artificial intelligence. However, Mehrotra took it a step further during the fiscal 2026 third-quarter earnings call. He predicted a "sustained, substantial multidecade memory demand cycle" that will begin in "the latter part of this decade."
This cycle hasn't even started yet, and it's supposed to be bigger than the one that's being powered by AI data center demand. And that forecast came from Mehrotra right after his company broke records and crushed its already ambitious guidance.
Why robots? Mehrotra also notified investors that AI infrastructure is accelerating the path to physical AI. That's a large category that includes humanoid robots. Tesla (TSLA +0.22%) has also been teasing its Optimus robots for a while, and is getting closer to commercializing them.
When mass production of those devices actually happens, it will be a substantial tailwind for Micron. The company said humanoid robots will carry 10 times the memory of the average L2+ vehicle. (L2+ is just an auto industry insiders' term for vehicles with enhanced advanced driver assistance systems.)
The supply shortages in the memory market will get worse if demand continues to accelerate. Micron will have a vast runway to sell chips at nosebleed margins. Barclays expects the market for humanoid robots to reach $200 billion in less than 10 years, while well-known tech bull Dan Ives of Wedbush Securities anticipates the industry will be worth trillions of dollars over the course of the next decade.
Investors don't have to guess which robotics company will win that race when they can buy a chipmaker whose products will be integral to the majority of humanoid robots. That's the pitch from Micron, and it's a pretty good one.
Apple's (AAPL 0.37%) outgoing CEO, Tim Cook, just announced a landmark partnership with custom-silicon specialist Broadcom (AVGO 0.31%). The agreement focuses on designing and producing custom silicon components alongside advanced wireless connectivity technologies for Apple's products. Apple's commitment to Broadcom signals deeper collaboration in specialized chips while supporting expanded U.S. production capacity.
Image source: The Motley Fool.
What do investors need to know about Apple's deal with Broadcom? Apple's deal with Broadcom exceeds $30 billion and is expected to produce more than 15 billion chips in the U.S. through 2031.
For Broadcom, the new agreement extends the company's custom ASIC work and includes a $1.5 billion investment to expand its facility in Fort Collins, Colorado. For Apple, the deal is part of the company's American Manufacturing Program (AMP), which aims to bring more manufacturing to the U.S.
Today's Change
(
-0.31
%) $
-1.25
Current Price
$
399.87
Why does Broadcom's deal with Apple matter for AI infrastructure? Custom ASICs are becoming central to the artificial intelligence (AI) infrastructure narrative because these specialized chips deliver superior power efficiency and performance for specific workloads when benchmarked against general-purpose GPUs.
Broadcom has a competitive edge in the ASIC market due to the company's design expertise and advanced manufacturing capabilities -- particularly in high-speed networking silicon that connects massive clusters of AI accelerators.
While this specific agreement centers on wireless and connectivity components for Apple's consumer devices, it underscores Broadcom's proven ability to execute large-scale custom silicon programs. This expertise supports the ongoing shift toward optimized, application-specific hardware that enables more efficient AI training and inference.
Is Apple's deal with Broadcom transformative? Wall Street analysts estimate that Apple accounts for 20% of Broadcom's revenue. A long-term commitment from Apple transforms Broadcom's AI business by providing substantial revenue visibility and helping justify the company's manufacturing expansion.
Moreover, working with Apple further diversifies Broadcom's ASIC portfolio beyond existing hyperscaler collaborations -- including design work for Alphabet's Tensor Processing Units (TPUs) and partnering with Meta Platforms on custom XPU platforms.
I see the deal with Apple as further evidence that Broadcom is becoming increasingly embedded in hyperscale data centers, allowing the company to rapidly scale its contributions across both device-level and infrastructure-level custom silicon.
Adam Spatacco has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Apple, Broadcom, and Meta Platforms. The Motley Fool has a disclosure policy.
HP, Inc. is a high-yield, undervalued tech stock with a bullish technical setup and a nearly 5% dividend yield. HPQ demonstrates strong valuation and profitability grades, with recent upward revisions to EPS and revenue estimates supporting its investment case. Technical analysis shows HPQ trading above its 30-week EMA, with bullish momentum, volume, and relative strength versus the S&P 500.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Ekonom Scott Sumner v souvislosti s nedávným odchodem Alana Greenspana vzpomíná a rozebírá některé kroky a politiku tohoto známého centrálního bankéře. „Byl bezpochyby jedním z největších předsedů Fedu, možná vůbec největším. Jeho působení ale hodnotím trochu jinak než mnoho jiných,“ píše Sumner a pokračuje výčtem některých svých „kontroverzních“ názorů:
Ekonom si myslí, že Greenspan během svého funkčního období (tedy v letech 1987 až 2006) odvedl skvělou práci. Pomohl při „vytváření stabilního růstu nominálního HDP, ale není důvod se domnívat, že by si v roce 2008 vedl lépe než Bernanke.“ Veřejné komentáře Greenspana vedené k měnové politice v letech 2008 až 2009 podle Sumnera dokonce naznačují, že by se mýlil stejně, jako to učinilo vedení Fedu v těchto letech.
Na druhou stranu je ale podle ekonoma „Greenspanovi připisována příliš velká vina za finanční krizi v roce 2008. Tato krize totiž „nebyla způsobena deregulací, ať už ten výraz znamená cokoli… Finanční krizi způsobila kombinace morálního hazardu a napjaté finanční situace.“ Největší chybou Greenspana v této oblasti byla záchrana hedge fondu Long-Term Capital Management v roce 1998. Ta totiž podle ekonoma přispěla ke zhoršování problému morálního hazardu.
Do této oblasti morálního hazardu přitom podle ekonoma patří téma „too big to fail“. Tedy to, že některé finanční instituce jsou „příliš velké na to, aby padly,“ protože jejich bankrot by způsobil obrovské ztráty v celé ekonomice. Je jim tak v případě potíží poskytována pomoc ze strany vlády, což ale vytváří morální hazard. Tyto instituce totiž mohou kvůli takovému jednání z vlády tíhnout k rizikovým krokům s tím, že v případě úspěchu budou realizovat zisky. Ovšem v případě neúspěchu pokryje ztráty vláda, respektive daňoví poplatníci.
Sumner pokračuje s tím, že roky 1987 až 2006 by neměly být považovány za „Greenspanovu éru“, ale za „neokeynesiánskou éru konsensu“. Nebyl to totiž jen Fed, kdo pochopil výhody cílování inflace, které se stalo součástí celkově přínosné ekonomické politiky. „I další významné centrální banky přišly na to, jak cílovat inflaci pomocí přístupu podobného Taylorovu pravidlu. A to do značné míry vysvětluje, proč i ostatní rozvinuté země dosáhly v tomto období stejného úspěchu v cílování inflace jako Spojené státy.
Sumner také připomíná, že v roce 1996 Greenspan hovořil o „iracionálním nadšení“ na akciovém trhu. O několik let později bylo toto varování vnímáno jako dobrá předpověď dalšího vývoje. Ovšem podle ekonoma se Greenspan ve skutečnosti „evidentně mýlil, protože akcie nebyly v roce 1996 nijak nadhodnocené. Toto je jen jeden z mnoha příkladů toho, jak je lidské myšlení posunuté směrem k hledání bublin tam, kde ve skutečnosti neexistují.“ Greenspanovou největší předností byla pak podle ekonoma „jeho ochota brát vážně informace obsažené v cenách aktiv“.
SummaryGE Vernova is positioned as a leader in the nuclear renaissance, leveraging 65 years of experience and a robust global presence.GEV's BWRX-300 Small Modular Reactor is commercially contracted, with construction underway in Canada and strong prospects in Poland, the UK, and the US.Nuclear currently comprises 2.6% of GEV revenue, but SMR contracts could drive steady-state nuclear revenue to $2B/year, accelerating from 2026 onward.I rate GEV a buy, citing proven technology, early SMR commercialization, and significant growth potential in global nuclear demand. Monty Rakusen/DigitalVision via Getty Images
Investment Thesis Numerous articles have been written about GE Vernova (GEV) for good reasons. With the need for electric energy exploding, GEV is the world’s most complete and diversified company, spanning three sectors: Power, Electrification, and Wind. A small but growing part of the Power sector
559 Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of GEV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Author note: Seeking Alpha offers me the opportunity to articulate my thoughts and share them with other investors. I am not a financial advisor, and the information provided in this article is my point of view based upon research. Due diligence and/or consultation with your investment adviser should be undertaken before making any financial decisions, as these decisions are an individual's responsibility.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Meta has said it is discontinuing an AI feature launched this week that allowed users to generate images using public Instagram accounts, after drawing widespread criticism over privacy concerns, including from a Hollywood union.
“Our intent was to provide a useful creative tool and to give people control over whether their public content could be referenced in this way,” Meta said in a statement.
“We’ve heard the feedback that this feature missed the mark, so it’s no longer available,” it said.
Meta, owner of Facebook and Instagram, had launched Muse Image on Tuesday, its first image-generation model from Meta Superintelligence Labs. The feature, integrated into its Meta AI chatbot, can use photos as input and lets users edit generated images directly through sketches.
The feature soon faced backlash over privacy concerns and being an automatic opt-in for users.
Emmy-winning actor Hannah Einbinder, known for Hacks, criticised the feature on Instagram, saying it had been turned on automatically and urging users to turn it off.
SAG-AFTRA, the union representing actors and other media professionals, also urged members and other Instagram users on Thursday to opt out of the feature.
“Anything other than a clear and conspicuous opt-in for these types of uses of Instagram users’ images is unacceptable, and an utter miscalculation of public sentiment regarding the obvious dangers and harms inherent in such use,” SAG-AFTRA said.
Following Meta’s decision to remove the feature, SAG-AFTRA welcomed the move.
“With the dangers of nonconsensual digital replicas well known to all, a feature that encouraged that behavior is unwise. We appreciate its discontinuance. It is the responsible thing to do,” a union spokesperson said.
The reversal reflects increasing pressure on technology companies to give users clear control over how their publicly shared content is used by AI features.
Several Wall Street analysts initiated coverage and set price targets for Space Exploration Technologies (SPCX 4.51%) before the company even went public. But now many on the Street are getting in on the action.
Recently, 15 new analysts initiated coverage on SpaceX, providing their initial ratings and price targets. While there are a variety of opinions on the Street, no one is more bullish than Raymond James.
Analyst Brian Gesuale just gave SpaceX stock its biggest price target yet, and it's not even close. Here's what a $10,000 investment in SpaceX would be worth if Gesuale ends up being right.
Image source: The Motley Fool.
Twenty-seven Wall Street analysts have now issued price targets on SpaceX, and for the most part, sentiment is pretty bullish.
Twenty-two of the analysts have buy ratings on the stock, four recommend holding, and one recommends selling, according to TipRanks. The average price target implies 60% upside.
That's pretty good, considering SpaceX stock hasn't exactly crushed it since the initial public offering. While raising $86 billion is an incredible accomplishment and SpaceX still trades at over $1.9 trillion in market cap, the stock is barely above its opening-day price -- and that's after it joined several indexes, including the Nasdaq-100.
As if 60% upside weren't enough, Gesuale has a massive $800 price target on SpaceX, implying multibagger returns and a market cap over $10 trillion.
Today's Change
(
-4.51
%) $
-6.86
Current Price
$
145.30
"We see the company as one of the defining industrial infrastructure companies of the 21st century," Gesuale said in a research note, according to Barron's. "Starship represents the defining industrial innovation of our generation."
Starship is SpaceX's heavy-lift, fully reusable rocket that is the key to unlocking orbital data centers, which many investors see as one of the big opportunities that will allow the company to capture massive market share in the data center compute market. Gesuale wrote that Starship can reduce the cost of transporting equipment into space by nearly 100% while significantly increasing payload capacity.
The analyst believes that SpaceX will play a role as important as the railroads and electrification did by transforming rocket launches "from a bespoke aerospace capability into a transportation network defined by commercial aviation-like operating cadence and continuously declining unit costs."
Gesuale is modeling for SpaceX to achieve $837 billion in revenue and $696 billion in earnings before interest, taxes, depreciation, and amortization (EBITDA) by 2031. He applied a 27x EBITDA multiple to arrive at his $800 price target.
Investors should apply a healthy dose of skepticism Raymond James is a well-respected firm, but I did not see the $800 price target coming -- not that it couldn't be right. If Gesuale is correct, a $10,000 investment would turn into $52,600. Not too shabby.
That said, I would encourage investors to apply a healthy dose of skepticism here. While I'm sure Gesuale and his team have done their due diligence, the price target uses some assumptions that one simply cannot know right now.
The first implies that Starship will be up and running within a few years and will conduct missions regularly. However, Starship had only completed 12 test flights as of May, so it's hard to know exactly when it will be ready for actual missions, let alone operate regularly.
Founder Elon Musk is known for doing the impossible, but it rarely happens on his predicted timeline. We also don't yet know what orbital data centers will cost and what the ultimate total addressable market (TAM) for orbital compute will be.
Gesuale sees a TAM of $30 trillion, which isn't far off from the total U.S. gross domestic product.
Again, he could be right, but investors need to prepare for either outcome: either he's wrong or SpaceX succeeds immensely but has only, say, a $15 trillion TAM. Another scenario is if the artificial intelligence trade suffers a big setback. With the stock already nearing a $2 trillion market cap, there could be serious downside if some of these massive assumptions don't play out.
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities.
“This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and development capabilities creates a clear path to getting this medicine to patients who need more treatment options.”
Under the terms of the agreement, Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar candidate. Teva will be responsible for regulatory submissions and, upon approval, commercialization of the intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey.
“This agreement is aligned with Teva’s Pivot to Growth strategy and our focus on expanding our biosimilars pipeline. With our global commercial footprint and deep expertise in complex medicines, we are well positioned to help bring this biosimilar candidate to patients,” said Yolanda Tibbe, Vice President, Global Head of Biosimilars at Teva.
This strategic agreement reinforces both organizations’ commitment to broadening access to biologic medicines while promoting the long-term sustainability of healthcare systems.
About ocrelizumab
Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, which are believed to play a role in the autoimmune activity associated with multiple sclerosis. Ocrevus® (ocrelizumab) is indicated for the treatment of relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. In the U.S., the intravenous formulation is marketed as Ocrevus®, while the subcutaneous formulation is marketed separately as Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq). In the EU, both formulations carry the single brand name Ocrevus®.
About Multiple Sclerosis
Multiple sclerosis is a chronic, unpredictable and progressive disease of the central nervous system, which includes the brain and spinal cord. In MS, the loss of myelin, the protective sheath surrounding nerve fibers, disrupts the transmission of electrical signals to and from the brain, leading to a wide range of symptoms.
MS affects people differently. Symptoms can fluctuate, with periods of worsening (relapses) followed by partial or full recovery (remission). Over time, some patients may also experience a gradual progression of disability.
Common symptoms include fatigue, weakness, numbness or tingling, walking difficulties, spasticity, dizziness, and vision problems, among others.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
About Polpharma Biologics
Polpharma Biologics International AG is a biopharmaceutical company focused on development and manufacturing of biosimilars for supply to global markets. We manage the entire value chain: from product selection and investment allocation, through program execution to asset monetization, ensuring fast progress from idea to launch in strong collaboration with our global partners.
Our international team of senior experts has proven experience in program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Working with trusted CDMOs and CROs, we deliver end-to-end biosimilars, from cell line to finished product, across a range of major therapeutic areas. Our commercial partners ensure access for patients to these medicines worldwide.
Our mission is to accelerate access to biologics. To fulfill that mission, we maintain a robust, expanding pipeline of biosimilars in development. www.polpharmabiologics.com
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute our collaboration agreement with Polpharma Biologics for the commercialization of its biosimilar candidate to ocrelizumab, upon regulatory approval; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-looking statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
